NCT04625946CompletedPhase 4
Metformin as an Adjunctive Therapy to Catheter Ablation in Atrial Fibrillation
Source: ClinicalTrials.gov · Last updated 6 Oct 2026
Brief summary (registry, in English)
This clinical trial is being done to determine if metformin, a drug which is normally used in diabetes, can reduce atrial fibrillation in patients who are having an ablation for atrial fibrillation (AF). Atrial fibrillation is an abnormal heart rhythm which research has shown is related in part to obesity and diabetes. It is anticipated that the participants treated in the metformin arm will have greater freedom from recurrent atrial arrhythmias after ablation. Eligible participants enrolled in the trial will be assigned to one of the treatment arms (no treatment or metformin) and have follow-up visits up to approximately 1 year after the ablation. Additionally, all patients will also receive education on lifestyle changes and exercise which are standard of care.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 117 (actual)
- First submitted
- 6 Nov 2020
- Start date
- 19 Jan 2021
- Primary completion date
- 1 Jul 2025
- Lead sponsor
- University of Michigan
- Diseases
- Atrial fibrillation
- NCT number
- NCT04625946
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 117
- From 19 Jan 2021 to the primary completion date, 1 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Individuals who are already taking metformin or other antidiabetic medications, including insulin
- Patients taking carbonic anhydrase inhibitors
Other illness
- Known diabetes
- History of significant alcohol use (\>2 drinks/day on average)
- History of New York Heart Association (NYHA) Class III or IV heart failure
Lab values
- Known allergy or Food and Drug Administration (FDA)-labeled contraindication to taking metformin (estimated glomerular filtration rate (eGFR)\<30 millilitres per minute (mL/min)/1.73 square meters (m2), hypersensitivity to metformin, acute or chronic metabolic acidosis)
- eGFR below 30 mL/min per 1.73 m2 or other clinical diagnosis of advanced renal disease
- Acute or chronic metabolic acidosis (serum bicarbonate \<22 milliequivalents per liter (mEq/L))
- History of hepatic dysfunction (serum bilirubin 1.5 times greater than ULN)
Other
- Pregnancy or nursing
Who the study is looking for
- Body Mass Index (BMI) \>25 kilograms / square meter (kg/m2) with plan for rhythm control of atrial fibrillation by catheter ablation
- All subjects must be able to understand and willing to sign a written informed consent document.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Michigan Coordinator of this site? Confirm its status | Ann Arbor | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.